Literature DB >> 10811979

Inhibition of prostate specific antigen expression by genistein in prostate cancer cells.

J N Davis1, N Muqim, M Bhuiyan, O Kucuk, K J Pienta, F H Sarkar.   

Abstract

Recent studies have provided convincing evidence for the role of soy-isoflavones, particularly genistein, in the inhibition of prostate cancer cell growth. Prostate specific antigen (PSA) is a biological marker used to detect and monitor the treatment of prostate cancer patients. Previous studies have documented that isoflavones can inhibit the secretion of PSA in the androgen-dependent prostate cancer cell line, LNCaP, however, the effects of genistein on androgen-independent PSA expression has not been explored. In this study, we have utilized a prostate cancer cell line, VeCaP, which expresses PSA in an androgen-independent manner, to determine the effects of genistein on cell proliferation and PSA expression. Here we show that genistein inhibits cell growth similarly in both the LNCaP and VeCaP cell lines, but has differential effects on PSA expression. We demonstrate using concentrations of genistein that have been detected in the serum of humans consuming a soy-rich diet, that genistein decreases PSA mRNA, protein expression and secretion. Conversely, only high concentrations of genistein inhibited PSA expression in VeCaP cells. Additionally, we have demonstrated that genistein inhibits cell proliferation independent of PSA signaling pathways, providing further evidence to support the role of genistein as a chemopreventive/therapeutic agent for prostate cancer irrespective of androgen responsiveness.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811979     DOI: 10.3892/ijo.16.6.1091

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

Review 1.  Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Subhash Padhye
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention.

Authors:  Eric A Klein
Journal:  Rev Urol       Date:  2002

3.  Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP.

Authors:  Florastina Payton-Stewart; Norberta W Schoene; Young S Kim; Matthew E Burow; Thomas E Cleveland; Stephen M Boue; Thomas T Y Wang
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

Review 4.  Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Treat Rev       Date:  2009-08-05       Impact factor: 12.111

Review 5.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

Review 6.  Perspectives on the role of isoflavones in prostate cancer.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Bin Bao; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  AAPS J       Date:  2013-07-04       Impact factor: 4.009

Review 7.  Cellular signaling perturbation by natural products.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong
Journal:  Cell Signal       Date:  2009-03-16       Impact factor: 4.315

Review 8.  Multi-targeted therapy of cancer by genistein.

Authors:  Sanjeev Banerjee; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-05-19       Impact factor: 8.679

9.  Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.

Authors:  Alex George; Idris Raji; Bekir Cinar; Omer Kucuk; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2018-02-16       Impact factor: 3.641

Review 10.  [A critical assessment of phytotherapy for prostate cancer].

Authors:  F G E Perabo; E C von Löw; R Siener; J Ellinger; S C Müller; P J Bastian
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.